Arbutus initiated at Buy at H.C. Wainwright on likely stock catalyst AB-720

 

• Arbutus Biopharma (ABUS +3.4%) was initiated with a Buy rating at H.C. Wainwright, PT $10.
• Analyst Ed Arce mentions that company is unique as an hepatitis B virus pure-play given that its management has designed and assembled a broad, proprietary portfolio.
• He further sees momentum building for AB-729, with "more definitive, positive" multi-dose data in Q1 "likely to represent a significant stock catalyst.
• As of Sep.30, 2020, cash balance stood at $118.3M; cash runway into mid-2022.
• https://seekingalpha.com/news/3645413-arbutus-biopharma-initiated-buy-h-c-wainwright-on-abminus-720-being-significant-stock